New website to unite cystic fibrosis patients and researchers

People with cystic fibrosis (CF) will be able to access the latest research findings about their condition, volunteer for clinical trials and influence the direction of future scientific studies through a new website being launched later this week.

CF Unite.org is the brainchild of academics at The University of Nottingham who wanted to find a way of bringing patients together to discuss scientific and medical breakthroughs without risking the spread of infections that can be dangerous to those living with the condition.

Dr Matthew Hurley, leading the CF Unite project in the University's School of Clinical Sciences, said: "There are a number of charities and groups that support CF patients with their condition but until now there has been nowhere that they can go to directly engage with the scientists and researchers who are studying the disease.

"Equally, patients with CF have a wealth of untapped experience because they live with the condition every day. This unique knowledge could be extremely useful in designing new clinical trials and in guiding experts on the type of research that is going to have the greatest impact."

Life-threatening disease

CF is the one of the UK's commonest life-threatening inherited diseases. It is caused by a faulty gene that controls the movement of salt and water in and out of the cells in the body, which leads to the internal organs, especially the lungs and digestive system, becoming clogged with thick sticky mucus.

People with CF are affected by bacteria which grow in the lungs. These are harmless to healthy people but could be potentially dangerous to other people with CF. These infections can usually be eradicated or kept at bay with early antibiotic treatment but bugs often eventually become established or become antibiotic-resistant, leading to patients' lungs becoming colonised.

The risk of cross-infection from such bacteria means that people with CF often have to avoid contact with others, which can lead to them becoming isolated.

The new website is a public engagement with science project which has been supported by a Wellcome Trust People Award. The site has been designed to work as a virtual 'conference,' where patients and their families will be able to access live webcasts of experts discussing the latest research findings and explaining the impact they could potentially have for people with CF. Patients will have the opportunity to ask the experts questions in real time.

Publicise and communicate

As the disease affects just 9,000 people in the UK researchers can often find it difficult to recruit enough patients on to clinical trials. CFUnite.org will offer academics and clinicians a shop window to publicise their future studies and to communicate with patients about how they can get involved.

The first virtual conference is set to take place on Saturday January 12 and the programme will include a discussion led by Dr David Sheppard from The University of Bristol on the new 'wonder drug' Ivacaftor, which is one of the most significant new treatments for some patients with CF in recent years.

The event will also include presentations on the results of clinical trials of Ivacaftor for two different types of CF mutations as well as a talk on the patient dimension by Ed Owen, CEO of the Cystic Fibrosis Trust.

CF patients and their families can access the site at www.cfunite.org, can follow on social media via Twitter via @CFUnite and Facebook/CFUnite.

Related Stories

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol will tell an audience at the BA Festival ...

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients ...

A London, Canada scientist studying cystic fibrosis (CF) has successfully corrected the defect which causes the overproduction of intestinal mucous in mice. This discovery by Dr. Richard Rozmahel, a scientist with the Lawson ...

Vancouver researchers have discovered the cellular pathway that causes lung-damaging inflammation in cystic fibrosis (CF), and that reducing the pathway's activity also decreases inflammation. The finding offers a potential ...

Aided by a new experimental model, scientists are a step closer to understanding how cystic fibrosis (CF) causes lung disease in people with the condition. The findings, published online April 28 in the journal Science Tr ...

Recommended for you

New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating ...

An analysis led by University of Cincinnati (UC) emergency medicine researchers shows that a simplified severity scoring tool for pulmonary embolism could be used in emergency departments to guide treatment ...

Women are more likely to have irritable bowel syndrome and other gastrointestinal (GI) disorders than men are. Although this could be because men and women handle the condition differently— "toughing it out" versus getting ...

Researchers at Upstate Medical University, in collaboration with a team of international investigators studying dengue fever, have discovered new information on climate drivers of the disease and social risk factors that ...

User comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.